



Two Consecutive Standardized Skin Surface Biopsies: An Improved Sampling Method to Evaluate Demodex Density as a Diagnostic Tool for Rosacea and Demodicosis

Fabienne M. N. FORTON¹ and Viviane DE MAERTELAER²

¹Dermatologist, rue Frans Binjé 8, BE-1030 Brussels, and ²Free University of Brussels (ULB), Institut de Recherche Interdisciplinaire en Biologie humaine et moléculaire (IRIBHM) & Service de Biostatistique et Informatique médicale (SBIM), Brussels, Belgium. E-mail: fabienne.forton@skynet.be

Diagnosing papulopustular rosacea is not always straightforward; no specific diagnostic test is currently available. A high density of Demodex mites is consistently observed in this condition. This retrospective study assesses an improved method for evaluating Demodex density among 1,044 patients presenting to our dermatology practice. The skin was cleaned with ether and Demodex densities were measured in 2 consecutive standardized skin surface biopsies taken from the same site. Mean densities in patients with rosacea and demodicosis were much higher than those in healthy controls and patients with other facial dermatoses. The optimal cut-off values for the 2 biopsies were combined and the resultant criterion (presence of a first biopsy density > 5 Demodex/cm² or a second biopsy density > 10 Demodex/cm²) enabled confirmation of a diagnosis of rosacea or demodicosis with a sensitivity of 98.7% and specificity of 95.5%, making this a valuable diagnostic tool for dermatologists in routine clinical practice.

Key words: Demodex; rosacea; demodicosis; acne vulgaris; seborrheic dermatitis; standardized skin surface biopsy.

Accepted Aug 29, 2016; Epub ahead of print Aug 30, 2016

Acta Derm Venereol 2017; 97: 242–248.

Corr: Fabienne Forton, rue Franz Binjé, 8, BE-1030 Brussels, Belgium. E-mail: fabienne.forton@skynet.be

Rosacea is a common dermatosis, affecting approximately 10% of the population in Sweden (1). It is defined by the consensus of the National Rosacea Society (NRS) as a central face distribution of at least 1 of 4 primary features: flushing, persistent erythema, papules and pustules, or telangiectasia (2). Four subtypes of rosacea were defined by the NRS consensus: erythematotelangiectatic rosacea, papulopustular rosacea (PPR), phymatous rosacea, and ocular rosacea; and one variant (granulomatous rosacea), each associated with specific groups of symptoms (2). PPR is the most difficult to diagnose. It can be confused with other common dermatoses, such as acne vulgaris and seborrheic dermatitis, and can also coexist with these dermatoses (2–6). According to the consensus definition, 2 key clinical features are considered necessary for a diagnosis of PPR: persistent erythema and transient papulopustules (2). At present, no diagnostic test is available.

Demodicosis is also a frequent skin condition (3), but is underdiagnosed (3, 7–9). The definition and classification of demodicosis are still being debated (10–12). Diagnosis is suggested by the presence of non-specific features, including follicular scales, redness, sensitive skin, pruritus, perifollicular macules or papules, atypical eczematiform eruption, folliculitis, isolated inflammatory papules and pigmentation (3, 11–17) and confirmed by the presence of a high density of Demodex mites (3, 7, 10, 11, 13, 14, 18, 19) and by clinical cure after acaricidal treatment along with normalization of Demodex density (Dd) (14, 15, 17, 19).

Although a pathophysiological role of Demodex is generally accepted in demodicosis, it remains controversial in PPR (12, 20). Nevertheless, high mean Dds are consistently observed in PPR (18, 21–27), cases of PPR with low Dd values are rare (12.5–16%) (3, 25) and topical acaricidal treatment has been shown to have beneficial effects in patients with PPR, supporting a key role of the mite in this condition (19, 28). It is also beginning to be accepted that Demodex mites are one of numerous triggering factors for Toll-like receptor 2, which is implicated in the immune reaction observed in PPR (29).

In 1971, Marks & Dawber (30) described the skin surface biopsy, a method in which the superficial part of the horny layer of the skin and the follicular content are sampled, allowing the presence of *Demodex folliculorum* (which mainly lives in hair follicles) to be detected. In 1993, we introduced the concept of “Demodex density”, and adapted the method of Marks & Dawber so that this density could be measured; we standardized the surface to be analysed and called this method the standardized skin surface biopsy (SSSB) (18). By comparing patients with rosacea with healthy controls, we proposed a cut-off value of 5 Demodex/cm² (D/cm²) for a diagnosis of PPR (18), which was subsequently confirmed and adopted by others (8, 31–36). This sampling method is quick and simple, reproducible, only slightly invasive, well-tolerated by patients (3, 37), cheap and, therefore, readily available to all dermatologists; however, its sensitivity is not very high (55%) (18, 38). In 1998, to increase the sensitivity, we proposed that the skin and the biopsy slide should be cleaned with ether before the SSSB and that a second, and therefore deeper, SSSB should be performed at the same site immediately after the first (**Fig. 1**) (38).




Fig. 1. Demodex folliculorum dispersed along the follicles is collected by consecutive standardized skin surface biopsies (SSSBs). (A) Schematic representation of numerous Demodex mites, agglutinated at different levels (red arrows) inside the follicle. (B) Microscopic view ($\times 100$) of 12 *D. folliculorum* agglutinated at different levels of the follicle on a standardized skin surface biopsy (SSSB) (numbers next to the arrows indicate the number of mites at each level): this picture is relatively rarely observed because usually the follicle content breaks and the different levels are kept by stumps on the consecutive SSSBs. (C) Pityriasis folliculorum on the right cheek of a 41-year-old woman, with the lamina of the SSSB (18). The opisthosomas of the most superficial mites are visible as thin, white follicular scales at the base of the hair, giving a frosted appearance and a rough texture, often felt to be dry skin by the patient. SSSB1+SSSB2 are indicated on the figure. (D) Microscopic view ($\times 40$) of numerous *D. folliculorum* ($n=73$) as they usually appear on SSSB: 1 level of Demodex is observed in each follicle, with 1–9 D/follicle.

This approach has since been used by other groups (3, 19, 32, 37, 39, 40).

In the present study, we investigate for the first time the systematic use of this deeper second sampling for Demodex in groups of patients with PPR, demodicosis and healthy skin, but also in a group of patients with other facial dermatoses, particularly those that can resemble PPR clinically.

We determined optimal cut-off Dd values for each of the 2 consecutive samples, and combined these 2 values to obtain an overall diagnostic criterion. We then validated this criterion in patients with conditions already known to have high Dds, i.e. PPR and demodicosis.

Our aim was to provide a validated, improved and useful diagnostic tool to assist dermatologists in routine practice.

METHODS

Patients

This retrospective study was approved by the Erasme Hospital ethics committee. All patients attending our dermatology practice in Brussels between 2002 and 2010 with clinical symptoms and signs suggestive of PPR (rosacea with centro-facial papulopustules) or demodicosis were included in the study.

The PPR-suggestive group was subdivided into patients with “typical PPR” (i.e. centro-facial papulopustules with persistent erythema) and those with other forms (centro-facial papulopustules without persistent erythema, granulomatous rosacea, steroid-induced rosacea). The diagnosis of demodicosis was made by an experienced dermatologist based on the combined presence of several clinical features and signs suggestive of the diagnosis, e.g. follicular scales, papules, folliculitis, pigmentation, pruritus, etc. Each of the patients with a clinical diagnosis suggestive of PPR or demodicosis had 2 successive SSSBs performed.

Patients with other facial dermatoses and healthy control patients (carefully selected to avoid including pityriasis folliculorum or erythematotelangiectatic rosacea) were also included if the consultation time was sufficient for 2 SSSBs to be performed. Patients with an uncertain clinical diagnosis, young children (under 7 years of age) and patients who had previously been treated for demodicosis and were returning for follow-up were not included.

For each patient, the date of consultation, age, sex, clinical diagnosis, location of the SSSBs and Dd values were recorded. Some of the patients with demodicosis and some of the “PPR-suggestive” patients also had other facial dermatoses, which were recorded.

Sampling method

The SSSB is a sampling method in which 1 cm² of the superficial part of the horny layer and of the follicular content is collected (Fig. 1, Video S1¹) (18). In our study, the patient’s skin and the microscope slides were first cleaned with ether and 2 SSSBs were then performed consecutively at the same place, allowing measurement of 2 Dds (D/cm²) (superficial (SSSB1) and deep (SSSB2)). The sum of these 2 values (SSSB1+2) was also noted.

The SSSBs were performed at the site of the main skin lesions, preferably on the cheek, if affected (because the highest Dds have been observed here) (21, 23).

Statistical analysis

Continuous variables are given as means and standard error of the mean (SEM) (min–max) and qualitative variables as percentages.

Differences in continuous variables were compared between groups using an analysis of covariance (ANCOVA), including age and sex as covariates, followed by Sidak tests for multiple comparisons if required. In the absence of age and sex effects, continuous variables were compared using classical Student’s *t*-tests or Welch tests in case of variance inequality, or with an analysis of variance (ANOVA) followed by Sidak or Dunnett T3 multiple comparison tests, when required, according to the results of the Levene test for homoscedasticity. Differences in qualitative variables were compared between groups using exact χ^2 tests.

Statistical significance was considered when p was < 0.05 . All statistical tests were performed using IBM-SPSS (version 22.0) software (IBM Corp, Armonk, NY, USA). Cut-off threshold values were proposed following the criterion of Youden and calculated using MedCalc[®] V14 (Ostend, Belgium) statistical software.

RESULTS

A total of 1,044 patients were included in the analysis: 254 PPR-suggestive, 590 demodicosis, 180 other facial

¹<https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2528>

dermatoses, and 20 healthy controls (Fig. 2). The mean age was 44.6 years (range 7.4–98.3 years; SEM 0.5); 712 (68.2%) were women (Table SI¹). The mean ages of the healthy controls and the patients with other dermatoses were similar ($p=0.088$) as were those of the “PPR-suggestive” and demodicosis patients ($p=0.193$).

The cheek was the most frequent biopsy site in each group: 19/20 (95%) in the healthy controls, 143/180 (79.4%) for other facial dermatosis, 485/590 (82.2%) for demodicosis and 225/254 (88.6%) for PPR-suggestive patients.

The 2 consecutive SSSBs were generally well tolerated. Mild bleeding occurred in 3 of 1,046 patients (Fig S1¹): after the first SSSB in 2 patients (for whom the second SSSB was not performed and the patients thus excluded), and after the second SSSB in one patient.

Demodex densities

As expected, patients with demodicosis and PPR-suggestive patients had high mean Dds, whereas the healthy controls and patients with other facial dermatoses had low mean Dds (Table I). There were no statistically significant differences in Dds between any of the other facial dermatoses subgroups and the healthy controls. To identify the optimal cut-off values to differentiate between normal and abnormal Dds, the 2 groups with high mean Dds (“PPR-suggestive” and demodicosis) were grouped together as “Demodex +”, and the 2 groups with low mean Dds (healthy controls and other facial dermatoses) were grouped together as “Demodex –” (Fig. 2). Patients in the “Demodex –” group were younger (36.5 ± 0.9 vs. 46.5 ± 0.5 years, $p < 0.001$) and more likely to be female (75.0% vs. 66.6%, $p = 0.023$) than patients in the “Demodex +” group (Table SI¹).

There were no statistically significant differences in the mean Dds in the 4 subgroups of PPR-suggestive patients (data not shown). Patients with “typical PPR” (215/254) had much higher mean Dds (SSSB1: 90 ± 8.2 D/cm², SSSB2: 207.5 ± 13.6 D/cm² and SSSB1+2: 298.5 ± 19.4 D/cm²) than the “Demodex –” group (all $p < 0.001$),




Fig. 2. Constitution of the 4 groups on the basis of the clinical examination. The number of patients in each group is indicated in orange. ^a445 pityriasis folliculorum, 80 follicular eczematides, 44 folliculitis, 14 pigmentation (chloasma-like without pregnancy, hormonal disorder or contraceptive pill), 6 isolated inflammatory papules, 1 isolated ocular demodicosis. ^b70 acne vulgaris, 33 seborrhoeic dermatitis, 10 ulerythema ophryogenes, 7 atopic dermatitis, 8 contact dermatitis, 7 dry skin (+ eczematides), 7 irritation dermatitis, 6 hyperpigmentation, 5 folliculitis, 4 perioral dermatitis, 3 chronic lupus erythematosus, 20 others.

and slightly higher values than the demodicosis group ($p=0.018$ for SSSB2, $p=0.034$ for SSSB1+2, $p=0.474$ for SSSB1).

The mean SSSB2 was significantly higher than the mean SSSB1 in the “Demodex +” and “other facial dermatosis” groups (both $p < 0.001$) (Table I). The same trend was observed in the healthy controls, but was not statistically significant ($p=0.071$).

Among the 844 patients in the “Demodex +” group, 647 had demodicosis or PPR alone and 197 had an associated facial dermatosis (134 seborrhoeic dermatitis, 31 acne vulgaris, 16 both seborrhoeic dermatitis and acne vulgaris, and 16 others). The mean Dds were not influenced by the presence of another facial dermatosis (Table SII¹). Patients with seborrhoeic dermatitis or acne vulgaris only had a high Dd if they also had demodicosis (Table SIII¹).

Diagnostic test

The cut-off Dd values best able to differentiate between the “Demodex +” ($n=844$) and “Demodex –” ($n=200$) groups were > 5 D/cm² for SSSB1, > 10 D/cm² for SSSB2 and > 15 D/cm² for SSSB1+2 (Table II, Fig. 3). The optimal diagnostic criterion for PPR or demodicosis was found to be the combination of an SSSB1 > 5 D/cm² or an SSSB2 > 10 D/cm², which had a specificity of 95.5% for the “Demodex –”

Table I. Demodex densities in the different clinical groups

Clinical groups	Patients <i>n</i>	Demodex densities (D/cm ²)					
		SSSB 1		SSSB 2		SSSB 1+2	
		Mean ± SEM	Min–Max	Mean ± SEM	Min–Max	Mean ± SEM	Min–Max
Healthy controls	20	1.8 ± 1.1	0–23	5.1 ± 2.1	0–35	6.9 ± 2.9	0–45
Other dermatoses	180	0.4 ± 0.1	0–7	1.3 ± 0.3	0–27	1.8 ± 0.3	0–32
Demodex –	200	0.6 ± 0.1	0–23	1.7 ± 0.3	0–35	2.3 ± 0.4	0–45
PPR-suggestive	254	86.6 ± 7.3	0–756	197.0 ± 12.1	0–1,280	283.6 ± 17.2	0–1,464
Demodicosis	590	82.7 ± 4.2	0–624	172.2 ± 7.7	0–1,256	254.9 ± 10.3	0–1,440
Demodex +	844	83.9 ± 3.7	0–756	179.7 ± 6.5	0–1,280	263.5 ± 8.9	0–1,464

There were no statistically significant differences in mean Dds between the healthy controls and the other dermatoses group. There was no statistically significant difference in mean Dds between the PPR-suggestive group and the demodicosis group (but the difference was nearly significant for SSSB2 ($p = 0.052$)). The “Demodex –” group had much lower mean Dds than the “Demodex +” group, as well as than each group considered separately (PPR-suggestive, demodicosis) ($p < 0.001$ every time). The “Demodex +” group had higher mean Dds than the healthy controls (SSSB1: $p = 0.001$, SSSB2 and SSSB1+2: $p < 0.001$) and than the other dermatoses group ($p < 0.001$ every time). SEM: standard error of the mean; SSSB: standardized skin surface biopsy.

Table II. Cut-off values provided by the comparison of "Demodex +" (n=844) and "Demodex -" (n=200) groups

	Demodex densities (D/cm ²)		
	SSSB 1	SSSB 2	SSSB 1+2
Cut-off proposed	5	10	15
95% CI	3-6	6-17	14-15
Sensitivity, %	89.3	94.3	95.7
95% CI	87.1-91.3	92.5-95.8	94.1-97.0
Specificity, %	98.5	96	97
95% CI	95.7-99.7	92.3-98.3	93.6-98.9

SSSB: standardized skin surface biopsy; CI: confidence interval.

group and a sensitivity of 98.7% for the "Demodex +" group. This sensitivity was statistically significantly higher than that obtained for the method based on SSSB1 alone (98.7% vs. 89.3%, *p*<0.001) (Table II); the decrease in specificity (95.5% vs. 98.5%) was not statistically significant (*p*=0.140).

To validate this new diagnostic criterion, we also applied it to the 2 groups of patients already known to have high Dd values. The sensitivity was 99.2% for the "demodicosis" group (*n*=590) and 98.6% for the "typical PPR" subgroup (with persistent erythema) (*n*=215). Thus, with this criterion, only 6 of the 254 PPR-suggestive patients (2.4%) and 3/215 (1.4%) of the typical PPR patients had a normal Dd. Demodicosis with a normal Dd was very rare, occurring in only 5 (0.8%) of the patients. By contrast, there were 9 patients (4.5%) with high Dds in the "Demodex -" group (3/20 healthy controls and 6/180 with other facial dermatosis).

DISCUSSION

In daily practice, the clinical diagnosis of PPR and demodicosis is not always straightforward: clinical signs are non-specific, sometimes very discrete (e.g. the follicular scales of pityriasis folliculorum), and they can be atypical, mimicking other facial dermatoses. Moreover, these conditions may be present at the same time as other facial dermatoses in the same patient. At present, the diagnosis therefore relies largely on the clinical training and experience of the dermatologist. By developing and validating a more sensitive SSSB for the detection of

Dds, we therefore provide a useful diagnostic tool for PPR and demodicosis to assist dermatologists in routine practice.

Our results confirm the cut-off value of >5 D/cm² for the SSSB1 that we established in 1993 (18), but also suggest a cut-off of >10 D/cm² for SSSB2 and >15 D/cm² for SSSB1+2.

The sensitivity obtained for SSSB1 (89.3%) is higher than that in 1993 (55%) (18). This can be explained by the cleaning of the skin with ether prior to the biopsy. By performing a SSSB2, we further increased the sensitivity by 5% (89.3% to 94.3%), and by combining the cut-off values of the 2 SSSBs in an overall diagnostic criterion (SSSB1 >5 D/cm² or SSSB2 >10 D/cm²) we increased the sensitivity by 9.4% (89.3% to 98.7%) compared with a single SSSB, a statistically significant increase. This high sensitivity and specificity may partly be explained by the exclusion of patients with uncertain clinical diagnoses.

We have confirmed, using a more sensitive D method in a larger number of patients, that high Dds are associated with demodicosis and PRR, whereas low Dds are found in the skin of healthy subjects and in patients with other facial dermatoses. A limitation of our study could be the differences in age and sex among our patient groups. However, the statistical method used (ANCOVA) corrects for these potential confounders so that the observed differences in Dds cannot be explained by these demographic inequalities. We also showed that normal Dd values are rare in patients with PPR, even rarer than expected: only 1.4% (3/215) compared with 12.5% in 2005 (6/48) (3). This observation, combined with the high mean Dds in patients with PPR, does not formally prove the pathophysiological role of Demodex in PPR, but adds support to this hypothesis. The rare cases of PPR with low Dds may represent false-negative results: for example, they could represent patients with PPR associated exclusively with *Demodex brevis*, which live inside sebaceous glands and are therefore rarely collected by SSSB. Among the patients with demodicosis, those with low Dd values (0.8%, 5/590) may also represent false negatives or errors in clinical diagnosis.




Fig. 3. Distribution of the patients according to the cut-off values proposed based on the Youden index: >5 D/cm² for standardized skin surface biopsy (SSSB)1, >10 D/cm² for SSSB2 and >15 D/cm² for SSSB1+2.

Sattler and colleagues (25) recently proposed confocal laser scanning microscopy for the measurement of Dd. To compare the results of their study with ours, we converted the Dds expressed “per 8×8 mm” and “per 5×5 mm” by these authors into D/cm^2 . Using this crude estimation, 258.4 and 376.8 D/cm^2 , respectively, would have been found in their PPR patients and 54.2 and 89.6 D/cm^2 in their control patients (25). The values they observed in rosacea are comparable with our values for SSSB1+2 ($298.5 \pm 19.4 D/cm^2$ for PPR), suggesting that the depth analysed by 2 consecutive SSSBs may be roughly equivalent to the depth analysed by confocal laser microscopy. This also explains why their measured Dds were much higher than those measured previously with only one SSSB. Indeed, our present study shows that the mean SSSB2 was approximately twice the mean SSSB1, suggesting that the majority of the *D. folliculorum* are located deep in the skin.

By contrast, the mean Dds in their control group far exceeded the values we found. The mean Dds of our healthy controls were very low, even after treating the skin with ether and performing 2 SSSBs, confirming previous findings (18, 21–24, 41–45). This apparent discrepancy probably results from a difference in the selection of the healthy controls. In the present study, we took care not

to include patients with pityriasis folliculorum in our healthy controls, a condition that can be very discrete and difficult to identify (7–9, 11).

Confocal laser scanning microscopy requires expensive equipment that is not available to all dermatologists and this technique cannot therefore be proposed as a diagnostic tool in routine daily practice (46). Nevertheless, comparison with our dual SSSB procedure would be interesting and this non-invasive technique should be further investigated, especially for studying Dds in the scalp, where SSSB is not indicated (because of associated pain and the need for prior shaving).

None of our other facial dermatoses subgroups had higher mean Dds than the healthy controls, corroborating prior observations showing low Demodex prevalence (47, 48) or density (41) in lupus erythematosus compared with PPR; low prevalence (13, 49–51) and normal Dd (8, 41, 42) in acne vulgaris; no association between presence of Demodex and seborrhoeic dermatitis or atopic dermatitis (52); normal Dds in contact dermatitis (8); no Demodex in the skin or eyelashes of patients with seborrhoeic dermatitis or acne vulgaris contrary to those with rosacea (53); and lower Dds in eyelashes in patients with greasy scales than in those with cylindrical dandruff (54). These observations suggest that Demodex




Fig. 4. Demodicosis and rosacea can be associated with seborrhoeic dermatitis and/or acne vulgaris, and are therefore often underdiagnosed. Here we show 2 clinical examples in which 2 successive standardized skin surface biopsies (SSSB1+SSSB2 values) enabled confirmation of diagnosis during the consultation. (A–C) A 58-year-old man with seborrhoeic dermatitis associated with papulopustular rosacea (PPR) and rhinophyma. (B) Forehead with follicular and non-follicular scales and pustules. (C) Nose and left cheek showing telangiectasia, papules and scales involving the naso-labial folds. In this patient, the SSSB1 value is inside normal limits, but the SSSB2 confirms a diagnosis of PPR in addition to the seborrhoeic dermatitis. (D–F) A 17-year-old man with acne vulgaris associated with PPR. (E) Forehead showing comedones. (F) Right cheek showing papulopustules and follicular scales. Both the SSSB1 and SSSB2 values confirm a diagnosis of PPR in addition to the acne vulgaris.

proliferates only in PPR and demodicosis and not in other dermatoses, supporting our hypothesis of a causal relationship in which Demodex drives the inflammatory response: its proliferation is not just an epiphenomenon occurring as a result of an inflammatory process (11, 19).

Although high Dds have been observed in some studies in patients with acne vulgaris (9, 34) seborrhoeic dermatitis (8, 31) or irritation dermatitis (8), it is likely that these patients had undiagnosed pityriasis folliculorum or associated demodicosis. Indeed, dermatologists rarely diagnose demodicosis (7–9) and, moreover, acne vulgaris, seborrhoeic dermatitis and demodicosis fairly commonly occur together in the same patient (Table SIII¹, Fig. 4) (2–6, 8–11, 52, 55). We have observed in clinical practice that seborrhoeic dermatitis only becomes apparent after normalization of the Dd. Although this observation has to be confirmed, this may suggest that *Malassezia* and Demodex compete, and that when Demodex disappears, *Malassezia* can proliferate more easily. Demodex may, therefore, not be an aetiological factor in seborrhoeic dermatitis, as suggested by Karıncaoglu et al. (31), but rather may benefit from the same favourable environment. Indeed, sebaceous hyperplasia, which favours seborrhoeic dermatitis and acne vulgaris, may also create better living conditions for the Demodex mite (9, 11, 19, 55, 56). Thus, while a high Dd confirms a diagnosis of PPR or demodicosis, it does not exclude the presence of another dermatosis.

In conclusion, our study confirms that high Dds are associated with demodicosis and PRR, while low Dds are found in the skin of healthy subjects and of patients with other facial dermatoses. Although the role of Demodex is not yet established in rosacea and demodicosis, our study suggests that high Dds, measured using the improved sampling method presented, could be a valuable diagnostic tool for all dermatologists in routine clinical practice.

ACKNOWLEDGEMENTS

We thank M. Parmentier, V. del Marmol and C. Verhoeven, for their constructive remarks; K. Pickett and P. Strong for proofreading; our patients for agreeing to participate in the study and allowing us to publish their photographs; and all the medical doctors and dermatologists who regularly entrust us with rosacea patients.

FMNF occasionally works as a consultant for Galderma. VdM declares no conflict of interest.

REFERENCES

- Berg M, Lidén S. An epidemiological study of rosacea. *Acta Derm Venereol* 1989; 69: 419–423.
- Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odum R, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. *J Am Acad Dermatol* 2002; 46: 584–587.
- Forton F, Germaux MA, Brasseur T, De Liever A, Laporte M, Mathys C, et al. Demodicosis and rosacea: epidemiology and significance in daily dermatological practice. *J Am Acad Dermatol* 2005; 52: 74–87.
- Powell FC. Clinical practice. Rosacea. *N Engl J Med* 2005; 352: 793–803.
- McFalda WL, Roebuck HL. Rational management of papulopustular rosacea with concomitant facial seborrhoeic dermatitis: a case report. *J Clin Aesthet Dermatol* 2011; 4: 40–42.
- Aroni K, Tsagrioni E, Lazaris AC, Patsouris E, Agapitos E. Rosacea: a clinicopathological approach. *Dermatology* 2004; 209: 177–182.
- Hsu CK, Hsu MM, Lee JY. Demodicosis: a clinicopathological study. *J Am Acad Dermatol* 2009; 60: 453–462.
- Zhao Y, Peng Y, Wang XL, Wu LP, Wang M, Yan HL, et al. Facial dermatosis associated with Demodex: a case-control study. *J Zhejiang Univ Sci B* 2011; 12: 1008–1015.
- Zhao YE, Hu L, Wu LP, Ma JX. A meta-analysis of association between acne vulgaris and Demodex infestation. *J Zhejiang Univ Sci B* 2012; 13: 192–202.
- Chen W, Plewig G. Human demodicosis: revisit and a proposed classification. *Br J Dermatol* 2014; 170: 1219–1225.
- Forton FM, Germaux M-AE, Thibaut SC, Stene JJ, Brasseur TV, Mathys CL, et al. Demodicosis: descriptive classification and status of rosacea, in response to prior classification proposed. *J Eur Acad Dermatol Venereol* 2015; 29: 829–832.
- Baima B, Sticherling M. Demodicidosis revisited. *Acta Derm Venereol* 2002; 82: 3–6.
- Ayres S Jr, Ayres S. III. Demodectic eruptions (Demodicosis) in the human. *Arch Dermatol* 1961; 83: 816–827.
- Ayres S. Pityriasis folliculorum (Demodex). *Arch Dermatol Syph* 1930; 21: 19–24.
- Purcell SM, Hayes TJ, Dixon SL. Pustular folliculitis associated with Demodex folliculorum. *J Am Acad Dermatol* 1986; 15: 1159–1162.
- Seifert HW. Demodex folliculorum als Ursache eines solitären tuberkuloiden Granuloms. *Z Hautkr* 1978; 53: 540–542.
- Kim JH, Chun YS, Kim JC. Clinical and immunological responses in ocular demodicosis. *J Korean Med Sci* 2011; 26: 1231–1237.
- Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case control study using standardized skin surface biopsy. *Br J Dermatol* 1993; 128: 650–659.
- Forton F. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. *J Eur Acad Dermatol Venereol* 2012; 26: 19–28.
- Chen WC, Plewig G. Are Demodex mites principal, conspirator, accomplice, witness or bystander in the cause of rosacea? *Am J Clin Dermatol* 2015; 16: 67–72.
- Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. *J Am Acad Dermatol* 1993; 28: 443–448.
- Abd-El-Al AM, Bayoumy AM, Abou Salem EA. A study on Demodex folliculorum in rosacea. *J Egypt Soc Parasitol* 1997; 27: 183–195.
- Erbagci Z, Ozgoztasi O. The significance of Demodex folliculorum density in rosacea. *Int J Dermatol* 1998; 37: 421–425.
- El Shazly AM, Ghaneum BM, Morsy TA, Abdel Aaty HE. The pathogenesis of Demodex folliculorum (hair follicular mites) in females with and without rosacea. *J Egypt Soc Parasitol* 2001; 31: 867–875.
- Sattler EC, Maier T, Hoffmann VS, Hegyi J, Ruzicka T, Berking C. Non-invasive in vivo detection and quantification of Demodex mites by confocal laser scanning microscopy. *Br J Dermatol* 2012; 62: 1050–1052.
- Casas C, Paul C, Lahfa M, Livideanu B, Lejeune O, Alvarez-Georges S, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. *Exp Dermatol* 2012; 21: 906–910.
- Zhao Ya, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. *Arch Dermatol* 2010; 146: 896–902.
- Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. *Br J Dermatol* 2015; 172: 1103–1110.
- Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors.

- J Am Acad Dermatol 2015; 72: 749–758.
30. Marks R, Dawber RPR. Skin surface biopsy: an improved technique for the examination of the horny layer. *Br J Dermatol* 1971; 84: 117–123.
 31. Karıncaoglu Y, Tepe B, Kalayci B, Atambay M, Seyhan M. Is *Demodex folliculorum* an aetiological factor in seborrhoeic dermatitis? *Clin Exp Dermatol* 2009; 34: e516–520.
 32. Aydingöz IE, Dervent B. *Demodex folliculorum* in renal transplant patients revisited. *Dermatology* 2001; 203: 272–273.
 33. Aşkin U, Seçkin D. Comparison of the two techniques for measurement of the density of *Demodex folliculorum*: standardized skin surface biopsy and direct microscopic examination. *Br J Dermatol* 2010; 62: 1124–1126.
 34. Abdel-Badie Salem D, El-shazly A, Nabih N, El-Bayoumy Y, Saleh S. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of *Demodex folliculorum*. *Int J Infect Dis* 2013; 17:e343–347.
 35. Seyhan ME, Karıncaoglu Y, Bayram N, Aycan O, Kuku I. Density of *Demodex folliculorum* in haematological malignancies. *Int Med Res* 2004; 32: 411–415.
 36. Dolenc-Voljc M, Pohar M, Lunder T. Density of *Demodex folliculorum* in perioral dermatitis. *Acta Derm Venereol* 2005; 85: 211–215.
 37. Lacey N, Russell-Hallinan A, Powell FC. Study of *Demodex* mites: challenges and solutions. *J Eur Acad Derm Venereol* 2016; 30: 764–775.
 38. Forton F, Song M. Limitations of standardized skin surface biopsy in measurement of the density of *Demodex folliculorum*. A case report. *Br J Dermatol* 1998; 139: 697–700.
 39. Kligman AM, Christensen MS. *Demodex folliculorum*: requirements for understanding its role in human skin disease. *J Invest Dermatol* 2011; 131: 8–10.
 40. Murillo N, Aubert J, Raoult D. Microbiota of *Demodex* mites from rosacea patients and controls. *Microb Pathog* 2014; 71–72: 37–40.
 41. Lazaridou E, Apalla Z, Sotiraki S, Ziakas NG, Fotiadou C, Ioannides D. Clinical and laboratory study of rosacea in northern Greece. *J Eur Acad Dermatol Venereol* 2010; 24: 410–414.
 42. Okyay P, Ertabaklar H, Savk E, Erfug S. Prevalence of *Demodex folliculorum* in young adults: relation with sociodemographic/hygienic factors and acne vulgaris. *J Eur Acad Dermatol Venereol* 2006; 20: 474–476.
 43. Akdeniz S, Bahceci M, Tuzcu AK, Harman M, Alp S, Bahceci S. Is *Demodex folliculorum* larger in diabetic patients? *J Eur Acad Dermatol Venereol* 2002; 16: 539–541.
 44. Aydingöz IE, Mansur T, Dervent B. *Demodex folliculorum* in renal transplant patients. *Dermatology* 1997; 195: 232–234.
 45. Aydingöz IE, Dervent B, Güney O. *Demodex folliculorum* in pregnancy. *Int J Dermatol* 2000; 39: 743–745.
 46. Lacey N, Forton FM, Powell FC. *Demodex* quantification methods: limitations of confocal laser scanning microscopy. *Br J Dermatol* 2013; 169: 212–213.
 47. Perrigouard C, Peltre B, Cribier B. A histological and immunohistological study of vascular and inflammatory changes in rosacea. *Ann Dermatol Venereol* 2013; 140: 21–29.
 48. Brown TT, Choi EY, Thomas DG, Hristov AC, Chan MP. Comparative analysis of rosacea and cutaneous lupus erythematosus: histopathologic features, T-cell subsets, and plasmacytoid dendritic cells. *J Am Acad Dermatol* 2014; 71: 1000–1007.
 49. Skrlin J, Richter B, Basta-Juzbasic A, Matica B, Ivacic B, Cvrlje M, et al. Demodicosis and rosacea [letter]. *Lancet* 1991; 337: 734.
 50. Hojyo T, Dominguez L. Demodicosis y dermatitis rosaceiforme. *Med Cutan Ibero Lat Am* 1976; 2: 83–90.
 51. Ayres S Jr, Anderson NP. *Demodex folliculorum*: its role on the etiology of acne rosacea. *Arch Derm Syph* 1932; 25: 89–98.
 52. Tehrani S, Tizmaghz A, Shabestanipour G. The *Demodex* mites and their relation with seborrheic and atopic dermatitis. *Asian Pac J Trop Med* 2014; 7: S82–84.
 53. Morgan RJ, Coston TO. *Demodex* blepharitis. *South Med J* 1964; 57: 694–699.
 54. Gao YY, Di Pascuale MA, Li W, Liu DT, Baradaran-Rafii A, Elizondo A, et al. High prevalence of *Demodex* in eyelashes with cylindrical dandruff. *Invest Ophthalmol Vis Sci* 2005; 46: 3089–3094.
 55. Zhao YaE, Guo N, Xun M, Xu JR, Wang M, Wang DL. Socio-demographic characteristics and risk factor analysis of *Demodex* infestation (Acari: Demodicidae). *J Zhejiang Univ-Sci B* 2011; 12: 998–1007.
 56. Porta Guardia CA. *Demodex folliculorum*: its association with oily skin surface rather than rosacea lesions. *Int J Dermatol* 2015; 54: e14–17.